Results 121 to 130 of about 9,558 (217)

The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study. [PDF]

Lancet Glob Health
Han N, Loosli T, Anderegg N, Hauser A, Josi J, Davies MA, Johnson LF, Lessells R, Günthard HF, Egger M, Kouyos RD.   +10 more
europepmc   +1 more source

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. [PDF]

N Engl J Med
Rana AI, Zheng L, Castillo-Mancilla J, Bao Y, Sieczkarski S, Brooks KM, Lake JE, Fichtenbaum C, Heath SL, Belaunzaran-Zamudio PF, Klingman K, Fox L, Morton T, Stirratt M, Li JZ, Acosta EP, Venuto C, Galárraga O, Shoptaw S, Wohl D, Green M, Beijer C, Ferbas K, Jennings C, Shin K, Collahua R, Dorosh M, Wannamaker P, D'Amico R, Smith K, Spreen W, Vandermeulen K, Van Solingen-Ristea R, Wimbish C, Tashima KT, Landovitz RJ, ACTG A5359 LATITUDE Trial Team.   +36 more
europepmc   +1 more source

Dual Long-Acting Cabotegravir/Rilpivirine Plus Lenacapavir in Integrase Strand Transfer Inhibitor Resistance: A Case Report and Review of the Literature. [PDF]

Open Forum Infect Dis
Seo L, Reilly-Evans B, Garland J.
europepmc   +1 more source

Alternative Administration of Antiretroviral Therapy in People with HIV Unable to Swallow: A Scoping Review. [PDF]

HIV AIDS (Auckl)
Abdessamad H, Baroody C, Pogorzelski K, Jamaleddine W, Kitonga MS, Omar H, Amankrah SA, Allen-Brown K, Dandachi D.   +8 more
europepmc   +1 more source

Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series. [PDF]

Open Forum Infect Dis
Gutiérrez F, Fernández-González M, Ledesma C, García-Abellán J, López L, Bello-Perez M, Padilla S, García F, Masiá M.   +8 more
europepmc   +1 more source

The safety of cabotegravir in pregnancy: a systematic review and meta-analysis. [PDF]

BMC Infect Dis
Jasper A, Fourie W, Chetty S.
europepmc   +1 more source

Antiretroviral Treatment Switch Among Treatment-Experienced People with HIV. [PDF]

J Health Econ Outcomes Res
Chastek B, Mordi U, Christoph MJ, Le LB, Lim T, Majethia S, Trom C, Cohen J.   +7 more
europepmc   +1 more source

New drugs: Rilpivirine

Australian Prescriber, 2012
openaire   +1 more source

Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model. [PDF]

EBioMedicine
Srinivasan P, Zhang J, Edwards T, Dinh C, Green A, Little D, Singletary T, Mendoza M, Pan Y, Deyounks F, Johnson R, Lipscomb J, Kourtis AP, Heneine W, García-Lerma JG, Smith JM.   +15 more
europepmc   +1 more source

Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program. [PDF]

Open Forum Infect Dis
Havens JP, O'Neill J, Kubat M, Sunagawa SW, Davis JM, Fadul N, Lechner J, Bares SH.   +7 more
europepmc   +1 more source